共 119 条
[1]
Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90
[2]
Bray F(2017)Small-cell lung cancer: what we know, what we need to know and the path forward Nat Rev Cancer 17 725-737
[3]
Center MM(2018)First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer N Engl J Med 379 2220-2229
[4]
Ferlay J(2021)An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer Ther Adv Med Oncol 13 17588359211020529-28
[5]
Ward E(2015)Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest J Transl Int Med 3 24-122
[6]
Forman D(2012)Small-cell lung cancer: prognostic factors and changing treatment over 15 years Clin Lung Cancer 13 115-1939
[7]
Gazdar AF(2019)Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Lancet 394 1929-4544
[8]
Bunn PA(2006)Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 4539-460
[9]
Minna JD(2014)The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer Br J Cancer 111 452-518
[10]
Horn L(2016)Pretreatment albumin/globulin ratio predicts the prognosis for small-cell lung cancer Medicine (Baltimore) 95 e3097-1370